AIP
MDGL icon

Arrowpoint Investment Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Arrowpoint Investment Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Buy
5,865
+4,673
+392% +$2.39M 0.69% 24
2026
Q1 		$624K Buy
1,192
+821
+221% +$392K 0.55% 34
2025
Q4 		$216K Sell
371
-421
-53% -$215K 0.03% 98
2025
Q3 		$363K Buy
+792
New +$295K 0.36% 55

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowpoint Investment Partners's MDGL Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its Madrigal Pharmaceuticals (MDGL) stake by 392% in Q2 2026, buying an estimated $2.39M and bringing the position to 5,865 shares worth $3.15M. The position accounts for 0.69% of the portfolio, ranked #24.

Arrowpoint Investment Partners first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Arrowpoint Investment Partners held 5,865 shares of Madrigal Pharmaceuticals worth $3.15M as of Q2 2026.
  • Arrowpoint Investment Partners bought 4,673 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.39M.
  • Madrigal Pharmaceuticals made up 0.69% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #24 holding.
  • Arrowpoint Investment Partners first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.